Mutations in MLH1 (MutL homolog 1) or MSH2 (MutS homolog 2) account for 60% to 80% of cancers associated with Lynch syndrome [31,32,33,34,35,36,37,38]. The gene discussed is MSH2; the disease is Lynch syndrome.